CA
NZ
UK
AU
IND
US
● Oculis signed an asset purchase agreement for Privosegtor (ACT-01) and a preclinical candidate, ACT-02.
●Net Incomewas $15.7 million, against a $43.7 million loss a year earlier.
● Second-quarterRevenuewas $343,639, up from $56,325 in the first quarter.
● Cash, equivalents and marketable securities were $285.2 million.
● 2026 revenue guidance of $2.4 billion to $2.6 billion was reiterated.
● No confirmedEarningsrelease, contract win, guidance update, or analyst action was established to coincide with the move.
● NoEarningsreport, guidance change, product approval, financing, or management announcement has been verified to coincide with the session.
● SBFM shares closed at $0.839 on October 7, 2026, after a one-day advance of 110.78%, more than doubling in a single session.
● SXTC shares closed at $6.91 on October 7, 2026, after a one-day gain of 452.80%, the single most dramatic advancer of the session.
● No verifiedEarningsreport, clinical-trial readout, regulatory decision, partnership, or analyst action was behind the advance.
Please wait processing your request...